Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15254908 | 1.00 | EPHX2 (0.52) | EPHX2SLC9A1MAPTL3MBTL1HRH3 | |
| SCHEMBL5683647 | 1.00 | EPHX2 (0.52) | EPHX2SLC9A1MAPTL3MBTL1HRH3 | |
| SCHEMBL6250729 | 0.85 | MAPT (0.51) | EPHX2MAPTL3MBTL1MCL1GPR88 | |
| SCHEMBL225810 | 0.85 | EPHX2 (0.49) | EPHX2SLC9A1L3MBTL1MCL1GPR88 | |
| SCHEMBL2741827 | 0.85 | EPHX2 (0.49) | EPHX2SLC9A1L3MBTL1MCL1GPR88 | |
| SCHEMBL225811 | 0.85 | EPHX2 (0.49) | EPHX2SLC9A1L3MBTL1MCL1GPR88 | |
| SCHEMBL17146213 | 0.84 | MCL1 (0.55) | EPHX2SLC9A1MAPTMCL1GPR88 | |
| SCHEMBL17590033 | 0.84 | MCL1 (0.55) | EPHX2SLC9A1MAPTMCL1GPR88 | |
| SCHEMBL13929891 | 0.84 | MCL1 (0.55) | EPHX2SLC9A1MAPTMCL1GPR88 | |
| SCHEMBL15208924 | 0.84 | MCL1 (0.55) | EPHX2SLC9A1MAPTMCL1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825538-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2825538-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8765767-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2013138687-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | EPHX2 531/4885SLC9A1 126/4885MAPT 2644/4885 |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2C | EPHX2 2845/4885SLC9A1 1672/4885MAPT 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.